乳腺癌患者手术和化疗前后血清HER2 ECD水平的变化

Changes of Serum HER-2 Extracellular Domain Levels of Pre-and Post-Surgery and Chemotherapy in Breast Cancer Patients

目的探讨乳腺癌患者手术、化疗前后血清HER2 ECD水平变化的临床意义。方法用双抗体夹心ELISA法(酶联免疫吸附法)检测乳腺癌患者及其配对手术、化疗前后血清HER2 ECD水平,进行统计分析。结果乳腺癌患者血清HER2 ECD水平与正常人和良性乳腺病患者有明显差异(P<0.01);手术后59例乳腺癌患者血清HER2 ECD水平89.8%(53/59)下降,10.2%(6/59)升高,而33例良性乳腺病患者69.7%(23/33)下降,30.3%(10/33)升高,两者差异有统计学意义(P<0.05);血清HER2 ECD水平升高组(8/59)对化疗反应率100.0%(8/8),而非升高组(51/59)对化疗反应率74.51%(38/51),两者无差别(P>0.05)。结论动态监测乳腺癌患者血清HER2ECD水平对评价其手术、化疗疗效有一定的临床提示意义。

Objective To evaluate the clinical implication of variations in serum HER2/neu extracellular domain （ECD） levels before and after treatment of breast cancer patients.Methods Serum HER2/neu extracellular domain （ECD） levels of 59 breast cancer patients before and after surgery or chemotherapy were assayed by enzyme-linked immunosorbent assay （ELISA）.Results Significant different HER2 ECD levels were found between breast cancer and healthy women and benign mastopathia（P〈0.01）. 89.8% （ 53/59 ） of 59 breast cancer patients and 69.7% （ 23/33） of 33 benign mastopathia patients with decreasing levels of serum HER2/neu ECD after surgery showed difference between the two groups（P〈0.05）.100.0%（8/8）of patients with increasing levels of HER2 ECD（8/59）and 74.51%（38/51）of patients with non-increasing levels of HER2 ECD（51/59）responded to chemotherapy（P〉0.05）, showing no difference between the two groups.Conclusion Kinetic monitoring of the changes of serum HER-2/neu ECD levels in breast cancer patients may represent a valuable tool for evaluating clinical response to surgery and chemotherapy.